Gortec-reach trial
http://www.zlfzyj.com/CN/Y2024/V50/I04/327 WebGORTEC 2024-01 REACH trial with particular focus on skin toxicity. 2. Methods 2.1. Study design and participants This is an open-label, randomised, multicenter phase III study …
Gortec-reach trial
Did you know?
http://www.zlfzyj.com/EN/10.3971/j.issn.1000-8578.2024.22.1296 WebAbstract Given the important position and function of the hypopharynx, the preservation of organ function and survival improvement are equally important. The optimal role of multi-disciplinary combined treatment modality becoming increasingly important. The optimal laryngeal preservation strategy for hypopharyngeal cancer is under continuous exploration.
WebSep 21, 2024 · 1170O - An international randomized trial, comparing post-operative conformal radiotherapy (PORT) to no PORT, in patients with completely resected non-small cell lung cancer (NSCLC) and mediastinal N2 involvement: Characterisation of PORT efficacy in lung ART (IFCT-0503, UK NCRI, SAKK) Cécile Le Pechoux (Villejuif, CEDEX, … WebBackground and purpose: Radiotherapy (RT) with cetuximab is an alternative for advanced-stage head and neck squamous cell carcinoma (HNSCC) patients who are unfit for cisplatin treatment. As 5-year overall survival is below 50%, it is of interest to test PD-L1 immune checkpoint blockade (avelumab) with cetuximab-RT in the curative setting.
WebMar 5, 2024 · Initially, the trial was designed with 80% power (that required 295 deaths and 416 patients), which was increased to 88% in December, 2016, because the rate of enrolment was high so a power increase was authorised … Web16 Gortec, GORTEC-CHU Bretonneau, 37044 - Tours cedex/FR; 17 Medical Oncology Department, Centre Anticancer Antoine Lacassagne, 06189 - Nice/FR; ... In this phase II randomized trial, patients with non operated stage III-IVa-b SCC of oral cavity, oropharynx, hypopharynx and larynx and unfit for receiving high dose of cisplatin were enrolled. ...
Web1. Head and Neck Tumor Committee of Chinese Society of Clinical Oncology, China 2. Radiation Oncology Physicians Branch of Chinese Medical Doctor Association, China
WebSep 20, 2024 · According to results presented yesterday from the phase III GORTEC-REACH study in patients with squamous cell carcinoma of the head and neck (SCCHN), … star trek discovery ships imagesWebIn the phase Ib KEYNOTE-028 trial, pembro showed antitumor activity and manageable safety in a cohort of 27 patients (pts) with R/M NPC. KEYNOTE-122 (NCT02611960) is a multicenter, open-label, randomized phase III study to evaluate the efficacy and safety of pembro monotherapy vs chemo in pts with platinum-pretreated, R/M NPC. Methods star trek discovery shuttleWebMay 20, 2015 · Long-term results of GORTEC 2000-01: A multicentric randomized phase III trial of induction chemotherapy with cisplatin plus 5-fluorouracil, with or without … star trek discovery shuttle bayWebJan 21, 2024 · The GORTEC-REACH trial also enrolled 275 cisplatin-ineligible patients and randomized them to standard treatment with cetuximab and RT vs. the standard treatment plus avelumab. The 2-year PFS was numerically higher in the experimental arm at 44% vs. 31% for the standard of care, but the difference was not statistically significant [ 43 ]. star trek discovery staffel 4 trailerWebDec 21, 2016 · Randomized Trial of Avelumab-cetuximab-radiotherapy Versus SOCs in LA SCCHN (REACH) (REACH) The safety and scientific validity of this study is the … star trek discovery season four episode eightWebApr 8, 2024 · The phase III trial JUPITER-02 randomized 289 patients 1:1 to gemcitabine and cisplatin (GC) with either toripalimab, a humanized IgG4K monoclonal PD-1 antibody, ... These include KEYNOTE-412, GORTEC-REACH, GORTEC 2015-01, NRG HN004 (Clin-icalTrials.gov identi fi er: NCT03258554) ... star trek discovery staffel 3 imdbWebCetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell … star trek discovery staffel 4 pluto tv